Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Teresa AmaralFelix KieckerSarah SchaeferHenner StegeKatharina KaehlerPatrick TerheydenAnja GesierichRalf GutzmerSebastian HaferkampJochen UttikalCarola BerkingDavid Rafei-ShamsabadiLydia ReinhardtFriedegund MeierAnte KaroglanChristian PoschThilo GambichlerClaudia PfoehlerKai ThomsJulia TietzeDirk DebusRudolf HerbstSteffen EmmertCarmen LoquaiJessica C HasselFrank MeissThomas TuetingVanessa HeinrichThomas EigentlerClaus GarbeLisa Zimmernull nullPublished in: Journal for immunotherapy of cancer (2021)
Immunotherapy with nivolumab plus ipilimumab, particularly in combination with stereotactic radiosurgery or surgery improves OS in asymptomatic and symptomatic MBM.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- minimally invasive
- peritoneal dialysis
- prognostic factors
- white matter
- resting state
- functional connectivity
- multiple sclerosis
- patient reported outcomes
- acute coronary syndrome
- patient reported
- mesenchymal stem cells
- surgical site infection
- subarachnoid hemorrhage
- basal cell carcinoma